Friedrich M, Villena-Heinsen C, Farnhammer C, Schmidt W
Department of Obstetrics and Gynecology, University of the Saarland, Homburg/Saar, Germany.
Eur J Gynaecol Oncol. 1998;19(4):333-7.
In this study, the new antineoplastic agents titanocene dichloride and vinorelbine are compared to cisplatin and paclitaxel using a human ovarian cancer xenograft model.
Biopsy material from one native human ovarian carcinoma was expanded and transplanted into 48 nude mice. The animals were divided into six treatment groups: cisplatin 3x4 mg/kg, paclitaxel 5x26 mg/kg, vinorelbine 1x20 mg/kg, titanocene dichloride 3x30 mg/kg, titanocene dichloride 3x40 mg/kg and a control group treated with 0.9% saline. Treatment groups were evaluated in terms of average daily increase in tumour volume and average daily body weight increase of the nude mice based on slopes of least square regressions performed on individual animals. The slope factors alpha and beta of the body weight (alpha) and tumour volume changes (beta) within each group were calculated.
A statistically significant decrease (p<0.05) in body weight of the experimental animals was shown in groups treated with paclitaxel (alpha = -0.6878) and titanocene dichloride 3x40 mg/kg (alpha = -0.7194) compared to the control group which was treated with 0.9% saline (alpha = -0.2643). Significant body weight changes were not observed in the comparison of the remaining treated groups (cisplatin: alpha = -0.4552, vinorelbine: alpha = -0.5606, titanocene dichloride 3x30 mg/kg: alpha = -0.6173 to the control group. A significant reduction (p<0.05) of the increase tumour volume (vinorelbine: beta = 5.260, paclitaxel: beta = 0.478, titanocene dichloride 3x30 mg/kg: beta = 10.283, titanocene dichloride 3x40 mg/kg: beta = 5.768) was shown in treated groups except for cisplatin (beta = 18.722) compared to the tumour bearing control group (beta = 30.136). A statistically significant reduction of the increase in tumour volume occurred under paclitaxel medication compared to the group treated with cisplatin.
We found titanocene dichloride to be effective as vinorelbine and more effective than cisplatin. Vinorelbine seems to be a very effective antineoplastic agent with a significantly higher cytostatic effect than cisplatin. Both titanocene dichloride and vinorelbine provide new therapeutic options in women with ovarian carcinoma not responding to standard chemotherapies.
在本研究中，使用人卵巢癌异种移植模型将新型抗肿瘤药物二氯二茂钛和长春瑞滨与顺铂和紫杉醇进行比较。
将取自一名原发性人卵巢癌的活检材料进行扩增并移植到48只裸鼠体内。动物被分为六个治疗组：顺铂3×4mg/kg、紫杉醇5×26mg/kg、长春瑞滨1×20mg/kg、二氯二茂钛3×30mg/kg、二氯二茂钛3×40mg/kg以及用0.9%生理盐水治疗的对照组。根据对个体动物进行的最小二乘回归斜率，评估治疗组裸鼠的肿瘤体积平均每日增加量和体重平均每日增加量。计算每组体重（α）和肿瘤体积变化（β）的斜率因子α和β。
与用0.9%生理盐水治疗的对照组（α = -0.2643）相比，用紫杉醇（α = -0.6878）和3×40mg/kg二氯二茂钛（α = -0.7194）治疗的组中实验动物体重出现统计学显著下降（p<0.05）。在其余治疗组（顺铂：α = -0.4552，长春瑞滨：α = -0.5606，3×30mg/kg二氯二茂钛：α = -0.6173）与对照组的比较中未观察到显著的体重变化。与荷瘤对照组（β = 30.136）相比，除顺铂（β = 18.722）外，治疗组的肿瘤体积增加显著降低（p<0.05）（长春瑞滨：β = 5.260，紫杉醇：β = 0.478，3×30mg/kg二氯二茂钛：β = 10.283，3×40mg/kg二氯二茂钛：β = 5.768）。与用顺铂治疗的组相比，紫杉醇用药时肿瘤体积增加出现统计学显著降低。
我们发现二氯二茂钛与长春瑞滨一样有效，且比顺铂更有效。长春瑞滨似乎是一种非常有效的抗肿瘤药物，其细胞抑制作用明显高于顺铂。二氯二茂钛和长春瑞滨都为对标准化疗无反应的卵巢癌女性提供了新的治疗选择。
